However, benefits were paired with gastrointestinal side effects (nausea, vomiting) affecting 2550% of users, highlighting the need for personalized tolerance assessment before initiation
Subsequently, liraglutide (Saxenda) was approved in 2014 for the treatment of obesity up to a maximum dose of 3.0 mg subcutaneously once daily in people with a BMI 30 kg/m 2 , or 27 kg/m 2 and obesity-related co-morbidity [9, 17]
Medical Review This pages scientific content was reviewed for accuracy on 2026-07-29 By Dr
This guide will walk you through everything: what dark spots really are, why they appear, which treatments work best, and when its time to see a dermatologist
Experts recommend this because animal studies show possible harm to the fetus, and there isnt enough safety data in humans